生物工程口香糖或许能成为对抗与癌症相关微生物的一种方法。
Bioengineered chewing gum may offer a way to fight HPV and other microbes

原始链接: https://www.sciencedaily.com/releases/2026/08/260803080917.htm

宾夕法尼亚大学亨利·丹尼尔(Henry Daniell)领导的研究团队开发出一种生物工程口香糖,可作为对抗头颈部鳞状细胞癌(HNSCC)的新型工具。该研究已发表在《科学报告》(Scientific Reports)上,表明这种口香糖能有效针对与癌症进展相关的特定微生物。 该口香糖利用了含有 FRIL 的扁豆提取物。FRIL 是一种抗病毒蛋白,可将患者唾液和口腔冲洗样本中的 HPV 水平降低多达 93%。此外,研究人员还在口香糖中加入了蛋白质聚精(protegrin),这是一种抗菌肽,能在保护口腔有益菌群的同时,成功消除有害细菌,特别是牙龈卟啉单胞菌(Porphyromonas gingivalis)和具核梭杆菌(Fusobacterium nucleatum)。 与可能破坏口腔健康环境并诱发继发感染的传统放射疗法不同,这种靶向方法为管理癌症相关病原体提供了一种有前景的非侵入性手段。研究团队设想将这种口香糖作为一种经济且易获取的辅助疗法,以支持当前的癌症治疗,或作为预防感染和传播的预防性措施。目前,团队正着手准备临床试验,以进一步验证这些研究结果。

近期 Hacker News 上的一场讨论关注了生物工程口香糖的研究,这种口香糖取材于扁豆(lablab beans),作为一种抗病毒制剂,具有捕获 SARS-CoV-2 和流感病毒等病原体的潜力。 讨论延伸到了几个相关话题: * **口腔健康与木糖醇:** 用户探讨了木糖醇口香糖在抑制致龋菌方面已被证实的好处。虽然木糖醇通常安全有效,但也有人指出过量摄入会导致消化问题或心血管方面的担忧,且对宠物具有剧毒。 * **对替代医学的质疑:** 参与者驳斥了关于“药用蘑菇”可清除 HPV 的说法,指出其缺乏可靠证据,且作者的专业背景存疑。 * **颌骨形态:** 讨论中还涉及了使用“乳香”口香糖改善面部结构的旁支话题,触及了有关饮食和正畸的有争议理论。 * **微塑料:** 有人提出质疑,认为咀嚼任何口香糖(无论天然还是合成)是否都会导致微塑料摄入。 总体而言,虽然药用口香糖的前景在科学上令人感兴趣,但用户强调,在将其视为可行的医疗手段之前,必须进行严谨且可重复的临床试验。
相关文章

原文

Researchers have developed a bioengineered chewing gum that may offer a new way to target microbes associated with head and neck cancer. In tests involving oral samples from patients, extracts from the gum sharply reduced one virus and two types of bacteria linked to the disease.

The research team was led by Henry Daniell of the School of Dental Medicine at the University of Pennsylvania. The findings were published in Scientific Reports and could support the development of more accessible and affordable treatments.

A Need for Better Head and Neck Cancer Therapies

Head and neck squamous cell carcinoma (HNSCC) is a common form of cancer that begins in the tissues lining the mouth and throat. The disease can be particularly aggressive, and outcomes are often poor when it is discovered at a later stage.

Daniell says that many recently approved cancer medications have not produced major improvements in patients' quality of life or five-year survival. That limited progress highlights the need for new approaches that can work alongside existing treatments.

Targeting HPV and Harmful Oral Bacteria

The new study builds on earlier research involving chewing gum made from lablab beans (bean gum). The gum contains FRIL, a naturally occurring antiviral protein.

Daniell and his colleagues used oral samples from patients with HNSCC to study three microbes associated with cancer. These included human papillomavirus, or HPV, along with two bacterial species, Porphyromonas gingivalis (Pg) and Fusobacterium nucleatum (Fn).

"The global increase in oropharyngeal cancer is linked to HPV infection," says Daniell. "And Pg and Fn infections worsen survival rates of untreated recurrent or metastatic oral cancer, even after surgery and risk-adjusted adjuvant, or supplemental, therapies."

Gum Extracts Sharply Reduce Microbe Levels

Tests showed that extracts from the bean gum lowered HPV levels by 93% in saliva samples. HPV levels also fell by 80% in oral rinse samples.

The researchers then engineered the bean gum to contain protegrin, an antimicrobial peptide capable of killing harmful bacteria. A single dose brought levels of Pg and Fn down to almost zero.

Importantly, the treatment did not appear to harm the beneficial bacteria that normally live in the mouth. Radiation therapy can have a different effect, reducing helpful bacteria while encouraging the growth of disease-causing yeast (Candida albicans).

A Potential Addition to Cancer Treatment

The ability to target dangerous microbes while preserving the healthy oral microbiome could make the gum useful in several ways. Researchers believe it may eventually serve as an additional therapy alongside current cancer treatments or as a preventive measure against infection and transmission.

"Lip and oral cavity cancer was the seventh leading cancer type in cancer incidence and mortality rate worldwide in adolescents, young adults, and middle-aged adults in 2022," says Daniell. "Our findings support the value of advancing these therapies to clinical trials as adjuvants with current treatments or as prophylaxis to prevent infection and transmission."

Henry Daniell is the W.D. Miller Professor in the Department of Basic & Translational Sciences at the School of Dental Medicine at the University of Pennsylvania.

Other authors include Geetanjali Wakade, Rahul Singh, and Smruti Nair of Penn Dental Medicine; Andrés M. Bur and Sufi M. Thomas of the University of Kansas Medical Center; Eri S. Srivatsan and Marilene B. Wang of the University of California at Los Angeles; and Saroj K. Basak of the Veterans Administration Greater Los Angeles Healthcare System.

The research received support from NIH (grant 5-R01-HL 107904-13 awarded to Henry Daniell), the Academic Senate Grant of the David Geffen School of Medicine at UCLA (the Surgical Education Research program), and the National Cancer Institute Cancer Center (Support Grant P30 CA168524).

联系我们 contact @ memedata.com